Health
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021? – Motley Fool Australia
This smaller biotech company attracted a lot of attention in 2020, but is it still worth an investment?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna(NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year,…
-
Noosa News17 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business21 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General22 hours agoRush to buy homes before rate cuts send prices soaring
-
Business19 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025